New Diffractive Depth of Field–Enhancing Presbyopia-Correcting IOL: Early Results

Tuesday, April 21, 2015: 8:01 AM
Room 4 (San Diego Convention Center)
Alberto J. Aguayo Bonniard, MD
Christoph Kranemann, MD

To evaluate the efficacy and side effects of a novel diffractive depth of field enhancing presbyopia correcting intraocular lens (DFE IOL) vs. a diffractive multifocal intraocular lens (MFIOL)

24 patients were randomized to either group. Preoperative and postoperative topography/refraction/endothelial cell counts/macular OCT/IOL master measurements/ocular guidance and wavefronts were obtained.

Phacoemulsification surgeries were carried out using an ocular guidance system for IOL and incision placement and a visual axis identification for placement of the IOL.

The diffractive MFIOL group aimed for +.1 to +.25 in the distance eye and the diffractive DFE IOL group for -.5 to -.75 in the near eye.

Complications and postoperative symptoms were recorded.

13 patients were randomized to the diffractive MFIOL group. There were no significant differences in parameters between the groups preoperatively.

At 3 months both groups had a mean UCDVA of 20/18. The diffractive MFIOL group had a mean UCNVA of 20/18  vs. an UCNVA of 20/22 in the diffractive DFE IOL group. The mean intermediate vision was 20/30 in the diffractive MFIOL group vs. 20/20 in the diffractive DFE group P 0.03.

8/13 in the diffractive MFIOL group had dysphotopsiae at 3 months vs. 1/11 in the diffractive DFE IOL group P<0.01.

The novel diffractive DFE IOL appears to produce a good range of vision and a possible reduction in dysphotopsiae.